Oncopeptides Management
Management criteria checks 2/4
Oncopeptides' CEO is Sofia Heigis, appointed in Aug 2023, has a tenure of less than a year. total yearly compensation is SEK3.18M, comprised of 55.3% salary and 44.7% bonuses, including company stock and options. directly owns 0.02% of the company’s shares, worth SEK59.92K. The average tenure of the management team and the board of directors is 1.3 years and 6.6 years respectively.
Key information
Sofia Heigis
Chief executive officer
kr3.2m
Total compensation
CEO salary percentage | 55.3% |
CEO tenure | less than a year |
CEO ownership | 0.02% |
Management average tenure | 1.3yrs |
Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely
Feb 29Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?
Nov 14We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully
Jul 26Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Mar 25Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?
Nov 23CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | kr3m | kr2m | -kr249m |
Compensation vs Market: Sofia's total compensation ($USD294.02K) is about average for companies of similar size in the Swedish market ($USD252.27K).
Compensation vs Earnings: Insufficient data to compare Sofia's compensation with company performance.
CEO
Sofia Heigis (43 yo)
less than a year
Tenure
kr3,180,000
Compensation
Ms. Sofia Heigis, M.sc, was Chief Commercial Officer and Managing Director of Germany at Oncopeptides AB (publ) since 2022 until 07 August 2023 and also serves as its CEO since 07 August 2023. Ms. Heigis j...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | less than a year | kr3.18m | 0.020% SEK 59.9k | |
Chief Scientific Officer | 1.3yrs | kr4.84m | 0.88% SEK 2.6m | |
Founder | no data | no data | no data | |
Founder | no data | no data | no data | |
Founder | no data | no data | no data | |
Founder | no data | no data | no data | |
Founder | no data | no data | no data | |
Founder | no data | no data | no data | |
Chief Financial Officer | less than a year | no data | no data | |
COO & Deputy MD | 4.3yrs | no data | 0.12% SEK 358.2k | |
Director of IR & Communications | 1.3yrs | no data | no data | |
Head of Human Resources | 6yrs | no data | 0.000090% SEK 264.9 |
1.3yrs
Average Tenure
49yo
Average Age
Experienced Management: ONCO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Chairman of the Board | 6yrs | kr1.63m | 0.39% SEK 1.2m | |
Independent Director | 12.3yrs | kr355.00k | no data | |
Independent Director | 7.3yrs | kr682.50k | 0.012% SEK 35.2k | |
Member of Clinical Advisory Board | no data | no data | no data | |
Independent Director | 13.1yrs | kr627.50k | 0.058% SEK 172.1k | |
Independent Director | 6yrs | kr755.00k | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Independent Director | 5.4yrs | kr755.00k | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data |
6.6yrs
Average Tenure
65yo
Average Age
Experienced Board: ONCO's board of directors are considered experienced (6.6 years average tenure).